Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

109 results about "Angina pain" patented technology

Chest pain caused by coronary heart disease

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
Owner:MORNINGSIDE VENTURE INVESTMENTS

Quality control method of the Yixinshu Chinese traditional medicine for supplementing qi and for promoting blood circulation by removing blood stasis

The invention relates to a quality control method of Yixinshu traditional chinese medicine preparation for nourishing qi, restoring pulse, and activating blood circulation to dissipate blood stasis, belonging to medicine domain. The Yixinshu traditional chinese medicine preparation is composed of panax, astragalus root, radix salviae miltiorrhizae, lityturf root, chinese magnoliaving, chuanxiong rhizome and haw, with ability of nourishing qi, restoring pulse, activating blood circulation to dissipate blood stasis, nourishing yin and production of body fluid, applicable for the patients who suffer for deficiency of both vital energu and yin, heart-throb knotted pulse, chest oppression, chest pain, and angina pectoris of coronary heart disease. At present, on clinical usage, it is applied extensively in the treatment of angina pectoris, myocardial ischemia, various type of arrhythmias, atrial premature beat, chest pain, angina pectoris of coronary heart disease and so on. The said quality control method provides the criterion of detection, means of detection, technical method and so on for the associated production and detection mechanism, therefore the quality of Yixinshu traditional chinese medicine preparation can be better controlled to ensure the safety of the said preparation. The quality method can better guide the production to make the production process control more strict and reasonable, therefore the users could have an overall acquaintance with the product quality.
Owner:GUIZHOU XINBANG PHARMACEUTICAL CO LTD

Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
Owner:ARENA PHARMA

Compound medicine for pulse generating and treating coronary heart disease

The invention belongs to the medication technical field, which discloses the medicine and the preparation method for treating the coronary heart disease and miocardial infarction. The medicine is mainly prepared from ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali and Chinese angelica, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig and liquorice, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig, liquorice, danshen root, red peony root, radix notoginseng and safflower, according to certain ratios of weights. The invention can be made to any type of medicament that can be accepted by the clinic or pharmacology, which is the good quality oral preparation. The medicine has effects of Qi-replenishing, Yin-nourishing and pulse-invigorating and blood circulation activating to dissipate blood stasis and lipid lowing, which can be used to curing the chest distress, hard breathe, heart-throb, angina and arrhythmia caused by coronary heart disease and miocardial infarction, the recovery period of the cerebral thrombosis and the sequelae of the cerebral thrombosis, the effects are obvious.
Owner:SHANDONG XUANZHU PHARMA TECH CO LTD

Medicament for treating coronary heart disease and angina and preparation method of granular formulation thereof

The invention relates to a medicament for treating coronary heart disease and angina and a preparation method of granular formulation thereof. The medicament takes traditional Chinese medical scienceprinciple as a basis, adopts a pure traditional Chinese medicine formaula, is reasonably prepared from raw material medicines such as milk veteh, Pueraria lobata, mistletoe, Salvia Miltiorrhiza, hawthorn, rhizoma ligustici wallichii, and the like by weight, and is prepared and processed by extracting effective components combining with modern technology. The invention has the effects of nourishingQi, invigorating the circulation of blood, invigorating pulse and tonifying the kidney. The medicine provided by the invention combines various kinds of medicine for treating patients with the deficiency of vital energy or patients suffered from the deficiency of the kidney with the symptom of chest distress, palpitation, hypodynamia, giddiness, lassitude in loin and legs, and the like caused bycoronary heart disease and angina. The medicament provided by the invention can obviously reduce the whole blood viscosity, plasma viscosity, fibrinogen viscosity and hematokrit of rats with blood stasis by pharmacodynamic experiment, and can obviously accelerate RBC electrophoresis, which indicate that the medicament can obviously recover the stickiness, concentration, coagulation and gathering of blood stasis type and has the function of blood circulation invigoration.
Owner:SHAANXI HUALONG PHARMA

Use of CBx cannabinoid receptor modulators as potassium channel modulators

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.
Owner:SOLVAY PHARMA GMBH

Traditional Chinese medicine preparation for treating coronary heart disease and angina

The invention relates to a traditional Chinese medicine preparation for curing coronary heart disease and angina which is prepared by the following raw materials according to parts by weight: 18-22 parts of salvia miltiorrhiza, 4-6 parts of Sanchi, 17-23 parts of rubefacient, 13-18 parts of dalbergia wood, 13-18 parts of rhizoma corydalis, 7-11 parts of safflower, 18-22 parts of fleece-flower root, 25-35 parts of caulis spatholobi, 18-22 parts of myrrh, 13-17 parts of ginseng, 13-17 parts of cinnamon, 18-22 parts of epimedium, 4-6 parts of hairy deerhorn, 11-15 parts of glossy ganoderma, 7-9 parts of aweto, 12-18 parts of hemlock parsley, 8-12 parts of peach kernel, 13-17 parts of olibanum, 4-6 parts of scorpion, 4-6 of chilopod, 12-17 parts of the root bark of the peony tree. The preparation has the efficacy of activating Yang and removing obstruction and eliminating phlegm for resuscitation, and is suitable for relieving obstruction of Qi in chest, thoracic pain involving the back, serious pain and tesshin, cough, plenty sputum and breathless , tachycardia. 96 cases of the coronary heat disease are cured by the invention. 85 cases among the 96 cases have obvious effect, while 11cases have no effect. The total effective rate is 88 percent. 87 cases are followed after the medicine is stopped eating for three months, which have no recurrence.
Owner:蔡青

Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same

The invention belongs to the medical technical field and discloses a drug combination for the cardiovascular disease and the preparation method of the drug combination. The drug combination contains the pharmacodynamic components of the raw materials of drugs of danshen root, Szechwan lovage rhizome, panax notoginseng, milkvetch root and storax. In order to achieve a better curative effect, a leech, tonka beans and peach nuts can also be added into the drug combination; in order to further improve the curative effect, rosewood, axillary choerospondias fruit and earthworms can be added into the drug combination. The drug combination of the invention has the efficacies of promoting the circulation of qi to induce resuscitation, activating blood circulation for removing blood stasis, dredging channels for alleviating pain etc. and is used for preparing the drugs for remedying the cerebral infarction convalescence of the coronary heart disease, the angina pectoris or the arteriosclerosis, the syndrome of which belong to the qi stagnation and blood stasis with the symptoms of chest pain, oppression in the chest, shortness of breath, heart throb, inefficaciousness of limbs, inarticulacy etc. The drug combination of the invention can be made into any preparation type, which is acceptable in the clinic and the pharmacy, and the oral preparation is preferential.
Owner:吴浩山

Fructose diphosphate containing novel pharmaceutical composition injection for treating circulation system diseases

The invention provides an injection prepared from a novel composition which contains three medicines such as fructose diphosphate and the like, wherein the injection consists of the following components according to effective doses: 10-50g of the fructose diphosphate, 0.01-0.05g of isosorbide dinitrate and 100-1000ml of sodium hydrogen sulfite. The invention also provides preparation steps and a preparation method. The pharmaceutical composition is applicable to shock, coronary heart disease, angina, acute myocardial infarction, myocardial ischemia, cardiac failure and surrounding lesions. By adding the isosorbide dinitrate, myocardial oxygen consumption is reduced, oxygen supply is enhanced and the angina is relieved. In cooperation with and by expanding the application of the fructose diphosphate to clinical treatment, the medicine is safer and is more stable, and the medicine is capable of relieving irritant pain on a human body and enhancing a curative effect on treating circulation system related diseases. The preparation method comprises the following steps: sequentially stirring and dissolving the fructose diphosphate, the sodium hydrogen sulfite and the isosorbide dinitrate by virtue of injection water, decoloring with the addition of activated carbon, filtering and removing carbon; and filtering, sterilizing, filling and sterilizing.
Owner:邓学峰

Traditional Chinese drop pills for treating cardiovascular and cerebrovascular diseases and preparation method thereof

The invention discloses a new form of a traditional Chinese medicine compound and a preparation method thereof. The new form of traditional Chinese medicine compound is used for activating the circulation of blood, dissolving the blood stasis, promoting the restoration of consciousness, taking away the pain, dilating the blood vessel, increasing the coronary artery blood flow and treating the coronary heart disease and the cerebral arteriosclerosis. The preparation method of the traditional Chinese drop pills comprises the following steps: grinding szechuan lovage rhizome, safflower, alisma orientale, achyranthes, radix curcumae, polygala tenuifolia, rhizoma anemones altaicae, spina date seeds and liquorice powder into medical fine power of 150 mesh for later use; adding water to decoct aalvia miltiorrhiza, red paeony root, prepared radix polygoni multiflori, barbary wolfberry fruit, kudzu-vine root and earthworm for 2 hours with a dynamic counter current extraction method, wherein the water is four times the total amount of the aalvia miltiorrhiza, the red paeony root, the prepared radix polygoni multiflori, the barbary wolfberry fruit, the kudzu-vine root and the earthworm; filtering the decoction; concentrating the filtered decoction into thick paste; adding and evenly stirring the thick paste, the medical fine power and dear heart powder to molten polyethylene glycol 4000, wherein the proportion of the thick paste, the medical fine power and the dear heart powder to the molten polyethylene glycol 4000 is 4:7; uniformly mixing; keeping the temperature of the mixture at 70 DEG C; dripping the mixture into liquid paraffin at constant speed; leaching the prepared traditional Chinese drop pills and wiping out the liquid paraffin. Test proves that the traditional Chinese drop pills are more markedly improved in the curative effect and the bioavailability than the original capsules.
Owner:BEIJING ASIA EAST BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products